Boston Scientific Corporation $BSX Shares Purchased by Prudent Man Advisors LLC

Prudent Man Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 34.1% during the second quarter, Holdings Channel.com reports. The fund owned 14,654 shares of the medical equipment provider’s stock after purchasing an additional 3,727 shares during the quarter. Prudent Man Advisors LLC’s holdings in Boston Scientific were worth $1,574,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares during the period. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the 1st quarter valued at $27,000. Princeton Global Asset Management LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the 2nd quarter valued at $37,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday. Raymond James Financial raised their price objective on Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a report on Thursday, July 24th. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Friday. The Goldman Sachs Group restated a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a report on Wednesday. Finally, Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $123.77.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 in the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 1.3%

NYSE BSX opened at $101.08 on Friday. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $101.14 and its 200-day simple moving average is $102.08. The firm has a market cap of $149.78 billion, a PE ratio of 54.06, a P/E/G ratio of 2.34 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the firm earned $0.63 EPS. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.